A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer
Meng Zhou,1,* Xiaoyu Wang,1,* Jie Xia,2 Yating Cheng,1 Lichun Xiao,1 Yu Bei,3 Jianzhong Tang,3 Yadong Huang,1,3 Qi Xiang,1,3 Shiliang Huang2 1Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People’s Republic o...
Guardado en:
Autores principales: | Zhou M, Wang X, Xia J, Cheng Y, Xiao L, Bei Y, Tang J, Huang Y, Xiang Q, Huang S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a44677340d4d4e75a7133702580f5ee7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody
por: Daniela Luz, et al.
Publicado: (2021) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
por: Archibald M, et al.
Publicado: (2016) - Monoclonal antibodies in immunodiagnosis and immunotherapy